UroGen Pharma Ltd.
Nasdaq URGN · Ra'Anana, Israel
Works in Oncology · Renal & urogenital · Women's health
UroGen Pharma Ltd. is a clinical trial sponsor based in Ra'Anana, Israel, listed as Nasdaq URGN. It has 4 active clinical trials with 859 planned participants, in Oncology, Renal & urogenital and Women's health. Since 2021 it has completed 3 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq URGN
Pipeline · 4 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about UroGen Pharma Ltd
UroGen Pharma Ltd is lead sponsor of 4 active clinical trials on ClinicalTrials.gov, with 859 planned participants, in Oncology, Renal & urogenital, Women's health. Since 2021 it has completed 3 trials and stopped 1 early.
UroGen Pharma Ltd is based in Ra'Anana, Israel and is listed as Nasdaq URGN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with UroGen Pharma Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-29.
Approve Suite is not affiliated with UroGen Pharma Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.